Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-25, Stock:NVS, The news for the past five days is as follows:
2018-10-18: NEWS1: [$$] Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion.NEWS2: Close Update: Stocks Slump Thursday Amid Interest Rate, Economic Growth Concerns.NEWS3: Close Update: Stocks Slump Thursday Amid Interest Rate, Economic Growth Concerns.NEWS4: PTI Jumps Over 400% On CF Data, GRTS, YMAB March Ahead, NVS Acquires ECYT.NEWS5: PTI Jumps Over 400% On CF Data, GRTS, YMAB March Ahead, NVS Acquires ECYT.NEWS6: Health Care Sector Update for 10/18/2018: ECYT,EIGR,NVS,PTI,ACRS.NEWS7: Health Care Sector Update for 10/18/2018: ECYT,EIGR,NVS,PTI,ACRS.NEWS8: Endocyte&apos;s $2.1 Billion Deal Rewards Investors Who Stuck It Out.NEWS9: Novartis Missed Revenue Estimates in Q3 2018.NEWS10: Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion.NEWS11: Mid-Day Update: U.S. Stocks Skid as Mnuchin Pulls Out of Saudi Conference, Italian Rout Triggered by Draghi.NEWS12: Mid-Day Update: U.S. Stocks Skid as Mnuchin Pulls Out of Saudi Conference, Italian Rout Triggered by Draghi.NEWS13: FDA snubs Novartis bid to repurpose inflammation drug for heart attacks.NEWS14: Mid-Morning Market Update: Markets Open Lower; Philip Morris Profit Beats Estimates.NEWS15: Mid-Morning Market Update: Markets Open Lower; Philip Morris Profit Beats Estimates.NEWS16: Why Endocyte, Inc. Stock Is Soaring Today.NEWS17: Why Endocyte, Inc. Stock Is Soaring Today.NEWS18: Novartis buying cancer drug maker Endocyte for $2.1B.NEWS19: Novartis Reports Positive Long-Term Data From Cosentyx Trials.NEWS20: Novartis Gets Key Therapy -- For Almost 200 Times Its Last Price.NEWS21: Why Endocyte, Inc. Stock Is Soaring Today.NEWS22: Health Care Sector Update for 10/18/2018: ECYT, NVS, DHR, PTI, JNJ, PFE, ABT, MRK, AMGN.NEWS23: Health Care Sector Update for 10/18/2018: ECYT, NVS, DHR, PTI, JNJ, PFE, ABT, MRK, AMGN.NEWS24: Wall Street Tumbles Ahead of Opening Bell After Hawkish Fed Minutes.NEWS25: Wall Street Tumbles Ahead of Opening Bell After Hawkish Fed Minutes.NEWS26: Novartis Secures Prostate Cancer Treatment With Endocyte Deal.NEWS27: Novartis To Buy Endocyte In $2.1B Deal.NEWS28: Pre-Market Most Active for Oct 18, 2018 :  ECYT, PTI, AZN, ERIC, NOK, ACHC, QQQ, SQQQ, HSBC, NIO, LYG, NVS.NEWS29: Pre-Market Most Active for Oct 18, 2018 :  ECYT, PTI, AZN, ERIC, NOK, ACHC, QQQ, SQQQ, HSBC, NIO, LYG, NVS.NEWS30: US Futures Tumble After Hawkish Fed Minutes.NEWS31: US Futures Tumble After Hawkish Fed Minutes.NEWS32: The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs.NEWS33: Earnings Reaction History: Novartis AG, 66.7% Follow-Through Indicator, 2.6% Sensitive.NEWS34: Earnings Reaction History: Novartis AG, 66.7% Follow-Through Indicator, 2.6% Sensitive.NEWS35: Endocyte stock pops 50% on $2.1 bln Novartis acquisition.NEWS36: [$$] European Equities Market Talk Roundup.NEWS37: Novartis pushes deeper into nuclear medicine with $2.1 billion deal.NEWS38: Novartis: 3Q Earnings Snapshot.NEWS39: Novartis pushes deeper into nuclear medicine with $2.1 bln deal.NEWS40: [$$] European Corporate News Roundup.NEWS41: Endocyte Enters Into Agreement to be Acquired by Novartis for $24/Share.NEWS42: Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash.NEWS43: Novartis to buy cancer drugmaker Endocyte for $2.1 bln in cash.NEWS44: Novartis Q3 Profit Weak, Lifts FY18 Sales View, To Buy Endocyte; Stock Up.NEWS45: Novartis Q3 Profit Weak, Lifts FY18 Sales View, To Buy Endocyte; Stock Up.NEWS46: Novartis raises 2018 sales outlook as Entresto, Cosentyx accelerate.NEWS47: Shares of cancer drugmaker Endocyte surge 50% on Novartis&apos; $2.1 billion acquisition deal.NEWS48: Shares of cancer drugmaker Endocyte surge 50% on Novartis' $2.1 billion acquisition deal.NEWS49: Novartis to buy Endocyte for $2.1 billion in cash.NEWS50: Novartis CEO: No fundamental changes to operations from B....NEWS51: Novartis Q3 Profit Down; But Lifts 2018 Net Sales View.NEWS52: Novartis Q3 Profit Down; But Lifts 2018 Net Sales View.NEWS53: Novartis To Acquire Endocyte - Quick Facts.NEWS54: Novartis To Acquire Endocyte - Quick Facts.
2018-10-19: NEWS1: The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut.NEWS2: Today's Research Reports on Trending Tickers: Pfizer and Novartis.NEWS3: Novartis Announces Phase II Preliminary Results Of GEOMETRY Mono-1 Trial.NEWS4: Novartis Announces Phase II Preliminary Results Of GEOMETRY Mono-1 Trial.NEWS5: Novartis: Lutathera NETTER-1 Data Shows Improvement In PFS - Quick Facts.NEWS6: Novartis: Lutathera NETTER-1 Data Shows Improvement In PFS - Quick Facts.
2018-10-22: NEWS1: Novartis Announces Full Data From LIBERTY Study Of Aimovig.NEWS2: Novartis Announces Full Data From LIBERTY Study Of Aimovig.NEWS3: Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates.NEWS4: Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates.NEWS5: How Novartis’s Innovative Medicines Business Performed in Q3.NEWS6: Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates.NEWS7: How Novartis’s Business Segments Performed in the Third Quarter.NEWS8: Novartis Reports Third-Quarter Revenue Growth.NEWS9: BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?.NEWS10: BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?.NEWS11: BIIB, ALKS Q3 Earnings Due on Oct 23: What&apos;s in Store?.NEWS12: This tiny biotech spun a quick $2 billion from $12 million.NEWS13: Novartis Reveals New Data Analysis Of COMBI-AD Study Of Tafinlar With Mekinist.NEWS14: Novartis Reveals New Data Analysis Of COMBI-AD Study Of Tafinlar With Mekinist.
2018-10-23: NEWS1: How Is Novartis Valued?.NEWS2: Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT.NEWS3: Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT.NEWS4: Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT.NEWS5: How Novartis’s Alcon Performed in Third Quarter.NEWS6: How Novartis’s Sandoz Performed in the Third Quarter.NEWS7: Why Aduro Biotech Crashed 29.5% Today.NEWS8: Why Aduro Biotech Crashed 29.5% Today.
2018-10-24: NEWS1: Incyte (INCY) to Report Q3 Earnings: What's in the Cards?.NEWS2: Incyte (INCY) to Report Q3 Earnings: What's in the Cards?.NEWS3: A Performance Overview of Johnson & Johnson.NEWS4: Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG.NEWS5: Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG.NEWS6: What Analysts Recommend for Novartis after Q3 Earnings.

Answer: Rise